Literature DB >> 7537321

Lumbar neurolytic sympathetic blockades provide immediate and long-lasting improvement of painless walking distance and muscle metabolism in patients with severe peripheral vascular disease.

M Gleim1, C Maier, U Melchert.   

Abstract

Thirty patients with angiographically proven peripheral vascular disease (PVD) and intermittent claudication were treated with percutaneous lumbar neurolytic sympathetic blockade (NSB) using 1.5 mL ethanol 95%. Claudication had been progressive in all patients during conservative treatment. Median (range) painless walking distance increased from 95 (10-200) meters (m) before to 355 (25-1003) m immediately after NSB. Further improvement was seen during the 1-year follow-up, with two exceptions: one patient lost a leg after acute arterial embolism and another patient deteriorated after 6 months. In the latter case, a second NSB improved the walking distance again. One case of transient mild neuralgia of the L3 dermatome occurred. 31P-magnetic resonance investigations of the calf muscles before, during, and after a treadmill exercise were performed in seven patients: 1 week after NSB, the postexercise recovery of phosphocreatine was accelerated in all patients compared to the pre-NSB values. The accelerated recovery suggests an improved post-ischemic metabolic situation after chemical sympathectomy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537321     DOI: 10.1016/0885-3924(94)00070-2

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  4 in total

1.  [Repeated percutaneous chemical sympathectomy as a therapeutic option for treating PAD II].

Authors:  P Gaus; M Grabener; W Höche; P Saur
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

2.  [Not Available].

Authors: 
Journal:  Schmerz       Date:  1995-01       Impact factor: 1.107

Review 3.  Analgesia in the elderly. Practical treatment recommendations.

Authors:  M P Drage; S A Schug
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

4.  [Adenosine for treatment of ischemic pain in thromboangiitis obliterans. A case report].

Authors:  Philip M Lang; D Irnich
Journal:  Schmerz       Date:  2007-06       Impact factor: 1.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.